Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Abstract Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targeting of BCR-ABL1 and additional CML-related surviv...

Full description

Bibliographic Details
Main Authors: Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S. Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Minori Tamai, Thao T. T. Nguyen, Koshi Akahane, Takeshi Inukai, Leif Stenke, Daniel Salamon
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-04154-0

Internet

https://doi.org/10.1038/s41419-021-04154-0

Similar Items